Tisagenlecleucel (KYMRIAH), developed by Novartis, was the first approved CD19-directed CAR-T cell therapy and has transformed outcomes for pediatric and young adult patients with relapsed or refractory B-cell ALL. The therapy is currently approved in multiple regions worldwide for relapsed/refractory B-ALL and certain lymphoma indications. Building upon its success in advanced disease, investigators are now evaluating whether earlier intervention with CAR-T therapy can improve outcomes for patients identified as having an exceptionally high risk of relapse.

The Phase II CASSIOPEIA/COG AALL1721 study enrolled children and young adults with National Cancer Institute high-risk B-ALL who remained MRD-positive (≥0.01%) following frontline consolidation therapy. A total of 121 patients received tisagenlecleucel following lymphodepleting chemotherapy. The median follow-up after infusion was 38 months.

Efficacy Outcomes-

• Four-year OS was 85%. 

• DFS without censoring for new therapy was 71% at 3 years and 64% at 5 years. 

• DFS with censoring was 69% at 3 years and 62% at 5 years. 

• MRD negative rate post infusion was 95% at day 29 and 86% at 3 months. 

• Relapse occurred in 31 patients, among whom 7 relapsed after new therapy/SCT. 

• A second infusion was given in 41 (34%) patients; 58 (48%) patients received new anticancer therapy/SCT without prior relapse. 

• Median duration of B-cell aplasia was 5.6 months.

• Probability (95% CI) of ongoing remission and B-cell aplasia at 3, 6, and 12 months was 76%, 47%, and 31%, respectively.

Safety Outcomes-

• Following the first infusion, cytokine release syndrome (CRS) occurred in 37% (Grade ≥3, 2%) and immune effector cell-associated neurotoxicity syndrome (ICANS) in 3% (Grade ≥3, 1%). 

• All 18 deaths occurred after relapse and/or new therapy/SCT.

KOL Insights-

“Durable remissions were achieved with tisa-cel in patients with very high-risk B-ALL who were MRD positive at the end of consolidation, and this was achieved with very low rates of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.”– Expert Opinion

“The combination of high MRD clearance rates and manageable toxicity provides encouraging evidence for further exploration of CAR-T therapy in high-risk pediatric ALL.” – Expert Opinion

Conclusion-

B-cell acute lymphoblastic leukemia is the most common childhood malignancy, and while cure rates exceed 85% overall, patients with persistent MRD after frontline consolidation remain at substantially increased risk of relapse. Identifying effective strategies for this high-risk subgroup remains a major clinical priority.

The Phase II CASSIOPEIA/COG AALL1721 study demonstrated that tisagenlecleucel can induce high rates of MRD negativity and durable remissions in pediatric and young adult patients with MRD-positive high-risk B-ALL. The favorable long-term survival outcomes and low incidence of severe CRS and ICANS support further investigation of CAR-T therapy earlier in the disease course. As follow-up continues, these findings may help define a new treatment paradigm for patients with persistent MRD following frontline therapy.